Ketamine (with other agents)

Ketamine is a dissociative anesthetic agent classified as an N-methyl-D-aspartate (NMDA) receptor antagonist that has been a cornerstone of veterinary anesthesia for decades, including extensive use in small mammal medicine. The medication produces a unique state of dissociative anesthesia characterized by profound analgesia and unconsciousness while maintaining certain protective reflexes including those involving the airway. Unlike other anesthetic agents that produce generalized CNS depression, ketamine creates a functional dissociation between the thalamocortical and limbic systems, resulting in a cataleptic state where the patient appears conscious but is disconnected from environmental awareness and pain perception.

The history of ketamine in veterinary medicine spans over fifty years since its initial development in the 1960s. Originally synthesized as a safer alternative to phencyclidine (PCP), ketamine quickly gained popularity due to its wide margin of safety and ability to produce reliable anesthesia without significant cardiopulmonary depression. The medication became particularly valuable in exotic animal medicine where species diversity and limited pharmacological data made drugs with wide safety margins essential. In small mammal practice, ketamine combined with various sedative agents has become the standard approach for chemical restraint and anesthesia in situations where inhalant anesthesia is impractical or unavailable.

Ketamine is commercially available as an injectable solution at 100 mg/mL concentration under various brand names including Ketaset, Vetalar, and Ketaved. As a Schedule III controlled substance in the United States and similarly regulated in other countries, ketamine requires DEA registration for possession and use, with strict documentation of all administration. For small mammal patients, the high concentration often necessitates dilution or careful calculation of very small volumes to achieve appropriate dosing. The medication is typically combined with other agents in the same syringe for convenience, with excellent compatibility with most commonly used sedatives including medetomidine, dexmedetomidine, and midazolam.

The effectiveness and safety profile of ketamine in small mammals is generally excellent when the medication is used appropriately as part of combination protocols. Ketamine alone produces poor muscle relaxation, rough recoveries, and potential for emergence delirium, making it unsuitable for solo use in virtually all small mammal applications. However, when combined with alpha-2 agonists, benzodiazepines, or other sedatives, ketamine contributes valuable dissociation, analgesia, and unconsciousness to balanced anesthesia protocols. The medication maintains cardiovascular function better than many other anesthetics, provides meaningful somatic analgesia, and has predictable duration of action. These characteristics, combined with decades of clinical experience across diverse species, have established ketamine combinations as reliable options for small mammal sedation and anesthesia.

Ketamine serves multiple essential purposes in small mammal medicine when combined with appropriate adjunct medications. The primary application is chemical restraint for minor procedures including examinations, sample collection, wound care, and diagnostic imaging in patients where physical restraint is impossible, dangerous, or excessively stressful. Ketamine combinations produce reliable immobilization allowing thorough evaluation of fractious patients, collection of blood samples for diagnostic testing, treatment of injuries, and positioning for radiographic examinations. The degree of sedation achieved with ketamine protocols typically allows procedures that would be painful or impossible in conscious animals.

Species-specific applications of ketamine reflect its long history of use across virtually all small mammal species encountered in veterinary practice. In rabbits, ketamine combined with medetomidine or dexmedetomidine produces reliable sedation for minor procedures, though the species' sensitivity to respiratory depression requires careful monitoring. Ferrets respond predictably to ketamine combinations, making them valuable for the frequent procedures needed to manage common conditions in this species. Guinea pigs and chinchillas achieve adequate sedation with appropriate ketamine protocols, with attention to respiratory function given their sensitivity. Small rodents including hamsters, gerbils, rats, and mice have extensive documentation of ketamine use, particularly from laboratory animal medicine where standardized protocols have been developed and refined over decades.

Common conditions and scenarios requiring ketamine administration include fractious patient management when temperament precludes safe handling, painful conditions requiring chemical restraint for examination and treatment, and situations where patient movement would compromise procedure success or safety. Dental examinations and minor tooth work commonly employ ketamine combinations in rodents and rabbits with their continuously growing teeth. Abscess drainage, wound debridement, and minor mass removals can often be accomplished under ketamine sedation without requiring inhalant anesthesia. Emergency situations may necessitate rapid chemical restraint to permit examination and stabilization of traumatized or severely distressed animals.

Off-label applications of ketamine extend beyond sedation to include analgesia for certain chronic pain conditions and potential antidepressant effects that have received attention in human medicine. Low-dose ketamine protocols have been explored for providing analgesia in small mammals experiencing neuropathic or cancer-related pain when conventional analgesics prove inadequate. The medication's NMDA receptor antagonism may help prevent central sensitization and wind-up phenomena associated with chronic pain states. Some wildlife and field applications utilize ketamine combinations for immobilization of wild small mammals requiring medical intervention or research procedures, with appropriate protocols established for various species.

When selecting ketamine over alternative approaches, veterinarians consider factors including equipment availability, patient status, procedure requirements, and practitioner experience. Ketamine combinations are often preferred when inhalant anesthesia capability is unavailable or impractical, when patients are high-risk for inhalant techniques, or when rapid induction is needed without establishing IV access. The analgesic properties of ketamine make it advantageous for painful procedures compared to protocols relying solely on sedatives. Situations favoring alternatives include patients requiring precise titration of anesthetic depth, procedures requiring muscle relaxation beyond what ketamine combinations provide, and cases where the controlled substance regulations make ketamine less practical than non-controlled alternatives.

Dosing principles for ketamine in small mammals emphasize that the medication should virtually never be used alone and that specific combination protocols should be determined by veterinarians experienced in exotic animal medicine. Ketamine monotherapy produces inadequate muscle relaxation, poor sedation quality, and rough recoveries, making combination with sedatives essential for appropriate patient care. The dose of ketamine varies substantially based on which adjunct medications are used, as alpha-2 agonists, benzodiazepines, and opioids all reduce ketamine requirements through synergistic interactions. Individual patient factors including species, body condition, health status, and anxiety level further influence dosing decisions, necessitating veterinary consultation for all ketamine protocols.

Route of administration options for ketamine include intramuscular, intravenous, and subcutaneous injection, with IM administration being most common in small mammal practice. Intramuscular injection produces reliable absorption with onset typically occurring within 5-10 minutes depending on injection site and patient circulation. Intravenous administration enables rapid onset and precise titration but requires vascular access that may be challenging in small or fractious patients. Subcutaneous administration is sometimes employed but may result in less predictable absorption and delayed onset. The relatively small injection volumes needed for ketamine make administration technically straightforward compared to some other injectable agents, though combination mixtures increase total volume.

Frequency and duration of ketamine effects depend on dose, combination agents, and individual patient metabolism. Following IM administration of ketamine combinations, peak effects typically occur within 10-15 minutes and may persist for 30-60 minutes or longer depending on the specific protocol. Recovery from ketamine without reversal agents occurs gradually as the medication is metabolized. When reversible agents such as alpha-2 agonists are included in the protocol, administration of reversal agents can accelerate recovery, though ketamine effects persist until metabolized. Repeat dosing may be administered if procedure duration exceeds initial anesthesia but should be approached cautiously to avoid accumulation and prolonged recovery.

Species-specific dosing considerations reflect variations in ketamine sensitivity and metabolism among small mammals. Rabbits may demonstrate variable responses to ketamine combinations, with some individuals achieving light sedation while others become profoundly anesthetized at similar weight-based doses. Guinea pigs and chinchillas generally respond predictably to established protocols, though respiratory monitoring remains essential. Ferrets typically achieve reliable sedation with standard ketamine combinations. Small rodents including hamsters, gerbils, rats, and mice have well-documented ketamine protocols from laboratory animal medicine, though responses can still vary among individuals. Hedgehogs and sugar gliders have limited published data, requiring extrapolation and careful clinical judgment.

Compounding requirements for ketamine in small mammals primarily involve accurate measurement of small volumes from the concentrated 100 mg/mL formulation. While dilution is not always necessary, some practitioners dilute ketamine to facilitate accurate dosing in very small patients. Combination mixtures containing ketamine, alpha-2 agonists, and potentially opioids can be drawn up in a single syringe for convenient administration, with compatibility data supporting most common combinations. Calculations for combination protocols require careful attention to ensure appropriate doses of each component, and verification by a second person helps prevent potentially dangerous errors.

Administration tips for veterinary staff include several practical considerations for ketamine protocols. Accurate patient weighing immediately before dosing is essential given the relationship between body weight and appropriate dosing. Combination mixtures should be prepared carefully with verification of each component dose. Injection technique should ensure intramuscular deposition rather than subcutaneous placement when IM administration is intended. Following injection, patients should be placed in quiet, dimly lit environments to facilitate sedation onset and reduce emergence excitement. Monitoring equipment should be prepared before administration. Recovery should occur in padded environments to prevent injury during the ataxic phase, and heat support prevents hypothermia during the sedation and recovery periods.

Common side effects of ketamine in small mammals include those inherent to the medication's mechanism and those related to combination agents used in clinical protocols. Muscle rigidity and increased muscle tone represent characteristic ketamine effects that necessitate combination with muscle-relaxing agents such as benzodiazepines or alpha-2 agonists. Hypersalivation occurs frequently with ketamine administration, sometimes profusely, potentially compromising airway patency if the patient is positioned inappropriately. Eye effects include maintenance of palpebral reflexes and open eyes during anesthesia, requiring corneal protection with ophthalmic lubricant to prevent exposure keratitis. Purposeless movements including paddling and head weaving may occur, particularly during onset or recovery phases.

Gastrointestinal effects of ketamine and its combination protocols require consideration in hindgut-fermenting small mammals. While ketamine itself has minimal direct GI effects, the overall sedation-anesthesia episode reduces gut motility and can contribute to stasis in susceptible species. Rabbits, guinea pigs, and chinchillas face gastrointestinal stasis risk during any sedation event, with appropriate hydration, minimized anesthesia duration, and prokinetic consideration helping prevent complications. Salivation stimulated by ketamine may be swallowed, contributing to GI contents. Recovery appetite is usually maintained or quickly returns in uncomplicated cases, though prolonged anorexia warrants investigation for underlying problems.

Species-specific adverse reactions to ketamine reflect physiological differences among small mammals. Rabbits may exhibit significant respiratory depression when ketamine is combined with alpha-2 agonists, requiring enhanced monitoring and potential oxygen supplementation. Ferrets generally tolerate ketamine combinations well but may have prolonged recovery if hepatic function is compromised by underlying conditions such as liver disease secondary to adrenal or insulinoma pathology. Guinea pigs sometimes demonstrate marked hypersalivation requiring careful positioning to prevent aspiration. Hamsters and other small rodents can experience profound hypothermia during ketamine sedation due to small body size and high surface-area-to-volume ratios. Chinchillas require temperature monitoring to prevent both hypothermia and overheating.

Serious and rare side effects of ketamine include apnea, particularly when combined with other CNS depressants at higher doses or in sensitive individuals. Severe emergence delirium with vocalization and agitation can occur, especially if ketamine is used without adequate sedative adjuncts or if recovery occurs in stimulating environments. Hyperthermia has been reported in some species, though hypothermia is more common. Cardiac arrhythmias may occur in patients with underlying cardiac disease. Seizure activity is possible, particularly in species with low seizure thresholds. Allergic reactions are uncommon but have been documented. Prolonged recovery significantly exceeding expected duration warrants investigation for underlying causes.

Owners and veterinary staff should contact the veterinarian immediately if concerning signs develop during or after ketamine administration. Warning signs requiring urgent attention include absence of spontaneous breathing, blue or white coloration of mucous membranes indicating poor oxygenation or circulation, persistent seizure activity, failure to recover within expected timeframes for the protocol used, signs of aspiration including labored breathing or crackling lung sounds, and severe hyperthermia or hypothermia. Excessive salivation compromising airway patency requires repositioning and potentially suctioning. Emergence excitement that poses injury risk may require additional sedation or containment in padded recovery areas.

Species contraindications for ketamine are minimal, as the medication has been used successfully across virtually all small mammal species when appropriate combination protocols are employed. However, certain patient populations warrant particular caution. Species known to have adverse ketamine reactions based on prior experience should receive alternative agents. Animals with documented hypersensitivity from previous ketamine exposure require alternative protocols. No absolute species contraindications exist for ketamine in small mammals when used by experienced veterinarians with appropriate monitoring capabilities, though individual patient factors may make alternatives preferable.

Medical condition contraindications for ketamine relate primarily to the medication's effects on specific organ systems. Patients with increased intracranial or intraocular pressure may experience dangerous pressure elevation with ketamine, making it relatively contraindicated in head trauma cases and patients with known intracranial pathology. Significant cardiac disease, particularly hypertrophic cardiomyopathy or conditions where increased myocardial oxygen demand would be problematic, represents a relative contraindication. Patients with uncontrolled hyperthyroidism may have exaggerated cardiovascular responses to ketamine. Severe hepatic dysfunction can prolong ketamine effects due to altered metabolism. Patients in established status epilepticus present complex decisions, as ketamine may worsen some seizure types while improving others.

Age, pregnancy, and nursing status influence ketamine use decisions in small mammals. Neonatal animals may demonstrate prolonged effects due to immature hepatic metabolism and altered distribution characteristics. Geriatric patients with compromised organ function may require dose reduction and enhanced monitoring. Pregnancy is a relative contraindication, as ketamine crosses the placenta and can affect fetal physiology, though emergency cesarean sections may utilize ketamine when benefits outweigh risks. Nursing animals may transfer ketamine or metabolites through milk, with clinical significance not fully characterized in small mammals. Pediatric patients require careful weight-based dosing and close monitoring.

Situations when ketamine should not be used include absence of appropriate adjunct medications, as ketamine monotherapy produces unacceptable sedation quality and recovery characteristics. Facilities lacking adequate monitoring capabilities should not undertake ketamine anesthesia, as complications require timely recognition and intervention. Practitioners without experience in small mammal anesthesia and specifically with ketamine protocols should refer patients to qualified colleagues rather than attempting unfamiliar techniques. Non-compliance with controlled substance regulations precludes legal ketamine use. Situations requiring maintained consciousness for diagnostic purposes are inappropriate for dissociative anesthesia. Patients with known severe previous reactions to ketamine warrant alternative approaches.

Medications that should not be combined with ketamine or require careful consideration include other CNS stimulants that could potentially enhance ketamine's sympathomimetic effects. Theoretically, concurrent use of thyroid supplements or sympathomimetic medications could exaggerate cardiovascular stimulation, though clinical documentation in veterinary patients is limited. Medications that lower seizure threshold may interact with ketamine in species prone to seizures, though ketamine has both pro-convulsant and anti-convulsant properties depending on circumstances. Drug combinations producing excessive CNS depression when ketamine synergizes with high doses of other sedatives pose risks if doses are not appropriately reduced.

Interactions affecting ketamine efficacy involve medications that alter metabolism or compete for binding sites. Chloramphenicol may prolong ketamine effects through hepatic enzyme inhibition. Chronic phenobarbital or other enzyme-inducing medications could theoretically reduce ketamine duration through enhanced metabolism, though clinical significance in small mammals is unclear. The interaction between ketamine and inhalant anesthetics results in reduced inhalant requirements during maintenance, which is clinically useful but requires appropriate vaporizer adjustment to prevent overdose.

Interactions with supplements and dietary factors are not extensively documented for ketamine but deserve consideration. Herbal supplements with CNS-active properties could theoretically modify ketamine effects, though evidence is limited. Dietary status affects overall anesthesia safety, with appropriate fasting protocols balancing aspiration prevention against hypoglycemia risk in small mammals prone to rapid blood glucose fluctuations. No specific dietary restrictions are required before ketamine administration beyond standard preanesthetic fasting guidelines appropriate for the species.

Beneficial and intentional drug combinations with ketamine form the foundation of practical ketamine use in small mammal practice. Alpha-2 agonists including medetomidine and dexmedetomidine combined with ketamine produce excellent chemical restraint with analgesia, muscle relaxation, and partial reversibility through atipamezole administration. Benzodiazepines such as midazolam combined with ketamine provide muscle relaxation and anxiolysis while allowing flumazenil reversal if needed. Triple combinations incorporating ketamine, alpha-2 agonists, and benzodiazepines or opioids represent common protocols for various procedure types. Opioid addition enhances analgesia for painful procedures beyond ketamine's somatic analgesic effects. Local anesthetic techniques complement ketamine-based protocols for procedures requiring regional anesthesia. These intentional combinations are designed to leverage synergistic effects while mitigating ketamine's limitations, particularly inadequate muscle relaxation and potential for rough recovery when used alone.

Controlled substance regulations governing ketamine require strict compliance with applicable laws regarding possession, storage, documentation, and use. In the United States, ketamine is classified as a Schedule III controlled substance requiring DEA registration for veterinary facilities. All ketamine must be stored in locked compartments with access limited to authorized personnel. Documentation of each dose administered must include patient identification, date, amount used, and administering veterinarian. Regular inventory reconciliation helps identify any discrepancies that could indicate diversion. Similar regulations exist in other countries, and practitioners must be familiar with and compliant with local requirements. Violations of controlled substance regulations carry serious legal consequences including loss of licensure.

Species-specific warnings address particular sensitivities that influence ketamine protocol selection and monitoring. Rabbits require careful attention to respiratory function, as ketamine combined with alpha-2 agonists can produce significant respiratory depression in this species. Oxygen supplementation should be readily available, and monitoring should include respiratory rate and quality assessment. Guinea pigs commonly develop profuse salivation with ketamine, requiring careful positioning to prevent aspiration and potentially anticholinergic pretreatment in some protocols. Chinchillas must be maintained in appropriately cool environments during recovery. Gerbils have low seizure thresholds and should be monitored for seizure activity. Small rodents require aggressive thermal support throughout sedation and recovery.

Monitoring requirements during ketamine anesthesia encompass multiple parameters essential for patient safety. Respiratory rate and quality should be assessed continuously or at frequent intervals, with decreased respiratory effort indicating potential complications requiring intervention. Heart rate monitoring detects bradycardia from alpha-2 agonist components or tachycardia from ketamine's sympathomimetic effects. Temperature monitoring throughout the procedure alerts staff to developing hypothermia requiring thermal support. Assessment of anesthetic depth through response to stimulation guides decisions about supplemental dosing or procedure timing. Pulse oximetry provides continuous oxygen saturation monitoring when equipment appropriate for small mammals is available. Eye protection with ophthalmic lubricant prevents exposure keratitis during the procedure.

Human safety considerations for ketamine relate to its controlled substance status and potential for abuse in addition to direct pharmacological effects. Staff handling ketamine should be aware of its abuse potential and the importance of strict inventory control and documentation. Accidental self-injection can produce dissociative effects in humans, warranting immediate medical evaluation. Security measures for ketamine storage and handling help prevent diversion. Veterinary staff with personal history of substance abuse may benefit from assignment to roles not involving controlled substance handling. Pregnant staff should use standard precautions when handling ketamine.

Recovery management for ketamine anesthesia requires particular attention to environmental factors affecting emergence quality. Recovery should occur in quiet, dimly lit areas to minimize stimulation that could trigger emergence excitement or delirium. Padded recovery cages prevent injury during the ataxic phase when coordination is impaired. Observation should continue until protective reflexes return and the patient demonstrates coordinated movement. Heat support maintains body temperature during the vulnerable recovery period. Reversal agents for combination components (atipamezole for alpha-2 agonists, flumazenil for benzodiazepines) can accelerate recovery when indicated but do not reverse ketamine itself. Post-anesthetic care instructions should be provided to owners including activity restriction, monitoring for complications, and criteria for emergency contact.

Storage requirements for ketamine are governed by both pharmaceutical stability considerations and controlled substance security regulations. The medication should be stored at controlled room temperature between 15-30 degrees Celsius (59-86 degrees Fahrenheit), protected from light, and secured in locked storage accessible only to authorized personnel. Controlled substance storage requirements mandate double-lock systems in many jurisdictions, with logs documenting each access. The medication should remain in its original packaging until ready for use to protect from light exposure and maintain label information including expiration date and lot number. Storage areas should be organized to facilitate efficient inventory management and accurate record-keeping.

Shelf life and stability of ketamine extends throughout the manufacturer's expiration date when stored according to specifications. Unopened vials maintain stability for extended periods under appropriate conditions. Once the vial septum is penetrated, single-use vials should be used immediately and remaining contents discarded, while multi-dose vials may be used according to manufacturer guidelines, typically within 28 days of first entry when aseptic technique is maintained. Ketamine mixed with other medications in a syringe should be used promptly, as compatibility and stability of mixtures varies. Diluted ketamine preparations should be used immediately unless stability data supports extended storage. Visual inspection before use should confirm clear solution without precipitate or discoloration.

Safe handling and disposal of ketamine follows strict protocols for controlled substances in addition to standard pharmaceutical waste procedures. Personal protective equipment including gloves reduces exposure during handling. Care should be taken to avoid needle-stick injuries. Disposal of unused or expired ketamine requires documentation and compliance with DEA or equivalent regulatory requirements, which may include witnessed destruction, return to registered reverse distributors, or participation in authorized take-back programs. Empty containers must be handled according to controlled substance container disposal requirements. Sharps used for ketamine administration require disposal in appropriate puncture-resistant containers. Complete documentation of ketamine disposal is essential for regulatory compliance and should be maintained with controlled substance records.

Hamsters, gerbils, mice, and rats have extensive documentation of ketamine use from decades of laboratory animal research, providing substantial data supporting combination protocols in these species. Small rodents generally respond well to ketamine combined with alpha-2 agonists or benzodiazepines, achieving reliable chemical restraint for various procedures. These species are particularly susceptible to hypothermia during anesthesia, requiring prewarmed surfaces, ambient heat support, and temperature monitoring. Gerbils warrant particular attention regarding seizure risk, as the species has naturally low seizure thresholds that could potentially be affected by anesthesia. Recovery in small rodents should occur in warm, quiet environments with nest material provided for behavioral comfort.

Guinea pigs and chinchillas respond to ketamine combination protocols with adequate sedation for many procedures when appropriate doses are administered by experienced exotic veterinarians. Guinea pigs commonly exhibit marked hypersalivation with ketamine, requiring careful positioning to maintain airway patency and consideration of anticholinergic premedication in some protocols. Both species are hindgut fermenters at risk for post-anesthetic gastrointestinal stasis, making prompt return to feeding and prokinetic consideration important aspects of recovery management. Chinchillas require particular attention to environmental temperature, as their dense fur predisposes them to heat retention while their metabolism may slow during anesthesia. Respiratory monitoring is essential in both species.

Ferrets represent an important species for ketamine use due to their frequent need for sedated procedures and their generally predictable response to ketamine combinations. Common ferret conditions including insulinoma, adrenal disease, and lymphoma often require diagnostic and therapeutic procedures that benefit from chemical restraint. Ketamine combined with medetomidine or dexmedetomidine produces reliable sedation in ferrets with appropriate duration for most minor procedures. Unlike rodents and rabbits, ferrets can safely receive beta-lactam antibiotics if concurrent infection requires perioperative treatment. Blood glucose monitoring during procedures is advisable in ferrets with known or suspected insulinoma.

Hedgehogs and sugar gliders can be managed with ketamine combination protocols, though limited published pharmacokinetic data requires veterinarians to extrapolate from related species and exercise careful clinical judgment. Hedgehogs present handling challenges due to their defensive curling behavior, and ketamine combinations can facilitate uncurling and subsequent examination. Injection administration may require placing the medication into accessible muscle while the animal is partially curled. Sugar gliders are susceptible to stress-related complications and self-mutilation, making smooth anesthesia and recovery particularly important. Their small size necessitates precise dosing calculations. Both species should be managed by veterinarians with exotic animal experience who can adapt protocols based on individual patient response and available monitoring capabilities.

Same-class alternatives to ketamine include tiletamine, another dissociative agent available only in fixed-ratio combination with zolazepam (a benzodiazepine) as Telazol or Zoletil. This combination provides both dissociation and muscle relaxation in a single injection but lacks the flexibility of separate ketamine and benzodiazepine administration. Tiletamine-zolazepam has established protocols for some small mammal species and may be useful when simplified protocols are desired. Phencyclidine, the historical predecessor to ketamine, is no longer used clinically due to prolonged recovery and behavioral effects but is mentioned for historical context. No other NMDA antagonists are commonly used as primary sedative-anesthetic agents in small mammal practice, though other NMDA antagonists like memantine and amantadine have analgesic applications.

Different-class alternatives for achieving sedation and anesthesia include alpha-2 agonists, benzodiazepines, and injectable anesthetic agents used without ketamine. Alpha-2 agonists alone produce reliable sedation with analgesia and reversibility but may not provide sufficient chemical restraint for all procedures. Benzodiazepines alone typically produce unreliable sedation in small mammals and are not recommended as sole agents. Alfaxalone provides injectable anesthesia without the dissociative characteristics of ketamine and may be preferred when smoother induction and recovery are desired. Propofol offers another injectable option requiring IV access. Inhalant anesthetics including isoflurane and sevoflurane provide precise titration of anesthetic depth without injectable agents.

Combination therapy options with ketamine leverage its properties as part of balanced anesthesia protocols. Ketamine-medetomidine or ketamine-dexmedetomidine combinations represent widely used protocols producing chemical restraint with analgesia and partial reversibility. Addition of midazolam to alpha-2 agonist-ketamine protocols enhances muscle relaxation and allows reversal of two out of three components. Opioid supplementation including butorphanol or buprenorphine enhances analgesia for painful procedures. Low-dose ketamine combined with other agents may provide improved analgesia compared to those agents alone. Ketamine use for induction followed by inhalant maintenance represents a common approach when inhalant anesthesia equipment is available but mask induction is impractical. These combination approaches allow customization of protocols to individual patient needs and available resources.